Navigation Links
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 14, 2007 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced additional statistically significant results with BEMA Fentanyl in cancer patients with breakthrough pain in its Phase III efficacy clinical trial for the product.

Results were based on the company's continuing analysis of the secondary efficacy endpoints from the study. A key secondary endpoint was the SPID 15 (Summary of Pain Intensity Difference at 15 minutes), a measure of the speed of onset of the medication. The study data indicate that the SPID 15 was significantly higher on BEMA(TM) Fentanyl than with placebo.

On April 25, 2007, BDSI announced statistically significant results of its primary efficacy endpoint for the BEMA(TM) Fentanyl Phase III trial, SPID 30 (Summary of Pain Intensity Difference at 30 minutes). BEMA(TM) Fentanyl consists of a small, dissolvable polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of cheek) membranes. Upon administration, BEMA(TM) Fentanyl is designed to deliver a rapid, reliable dose of drug across the mucous membranes.

In addition to the SPID 15 endpoint, the company also reported that the overall global analysis of the treatment, which represents each patient's overall satisfaction with the product, was also found to be statistically superior to the placebo.

Dr. Andrew Finn, BDSI's Executive Vice President of Product Development, stated: "We are very pleased with the outcome of the results from our current secondary endpoint analyses from our Phase III efficacy study which, as previously announced, we plan to present along with other efficacy and safety data at an upcoming scientific forum to be determined. We are particularly pleased to see that the onset of analgesia with BEMA(TM) Fentanyl is rapid, since a quick onset of action is one of the anticipated features of delivering fe
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/2/2015)... , July 2, 2015 The ... & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting ... Forecast to 2020", Silage Inoculants & Enzymes Market is ... CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ages ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of ... immunoassay segment of the In-Vitro Diagnostics market, announced the selection of ... a portable diagnostic platform designed to produce test results with central ... , , ...
... , June 21 ERT (Nasdaq: ... to the pharmaceutical, biotechnology and medical device industries, announced ... the Tufts Center for the Study of Drug Development, ... The industry-wide report measures the current and anticipated adoption ...
Cached Medicine Technology:CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 2CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 3CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 4ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 2ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 3ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 4
(Date:7/2/2015)... ... 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry was fully ... to write his first poem, and three years later he was publishing an entire book ... sharing with the world. "I have always believed that the best way to lift yourself ...
(Date:7/2/2015)... ... , ... Global leader and compression innovator, SIGVARIS North America, is ... For style that’s quick on its feet, men will love this fun new way ... everywhere because a simple change in socks can dramatically help improve overall leg health ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... and Emerging Healthcare Delivery Coalition met for the late June Web-based session, the ... with new reimbursement schemes and managing high-risk patients through coordinated care. , During ...
(Date:7/2/2015)... ... July 02, 2015 , ... Facial ... care and precision. There is an art and science that goes into successful ... successfully reshaping the facial features and lives of more than 2,500 satisfied facelift ...
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at the ... $4 million through five federal grants to study a group of related mosquito-borne ... diseases. , The research will be conducted in the Regional Biocontainment Laboratory ...
Breaking Medicine News(10 mins):Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4
... low in obese women and a recent study accepted for ... Society, reports that mice whose mothers had low ghrelin levels ... Hormones involved in energy balance and metabolism, such as ... and humans. However ghrelin,s role in reproductive tract development remains ...
... Texas MD Anderson Cancer Center has been awarded a grant ... head and neck cancer radiation treatment, can be prevented when ... $2.7 million grant awarded by the National Cancer Institute (NCI) ... score from peer scientists evaluating grant proposals for NCI. ...
... , TUESDAY, March 22 (HealthDay News) -- The serious ... patients will develop pneumonia can be reduced by ... Pneumonia is a looming threat for trauma patients. ... an incidence of 40 percent to 60 percent, mainly ...
... are more likely to be female, suffer from a neurological ... to research published in the March issue of the ... have shown that alcohol abuse by the perpetrator plays a ... Lee Friedman, assistant professor of environmental and occupational health sciences ...
... recruiting patients for a new National Cancer Institute ... drug rosuvastatin is effective in the prevention of ... population studies have shown that patients taking statins, ... fewer colon polyps, which can lead to cancer ...
... Changes that occur in the airways of asthma patients ... interleukin-13 (IL-13) which stimulates invasion of airway cells called ... Duke University. The study is the latest effort by ... in airway remodeling that can cause breathing difficulties in ...
Cached Medicine News:Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Steroid May Help Cut Pneumonia Risk After Brain Trauma 2Health News:Steroid May Help Cut Pneumonia Risk After Brain Trauma 3Health News:Elderly victims of abuse often use alcohol or drugs, study says 2Health News:Jefferson clinical trial: Can a cholesterol drug prevent colon cancer? 2Health News:Protein associated with allergic response causes airway changes in asthma patients 2Health News:Protein associated with allergic response causes airway changes in asthma patients 3
... is a high precision optical system for ... the anterior eye segment, based on a ... Placido Disk. , GALILEI combines the advantages ... accuracy curvature data, while Scheimpflug imaging is ...
... The C-VUE 55 Toric Multifocal ... also have presbyopia with all day ... visual acuity at every distance. This ... wide range of parameters with ADDs ...
... Nicknamed the SRS, this new and innovative stent ... the office right at the chair with just ... medical grade silicone and is available in three ... separately). At each end of the stent is ...
... Using flying spot technology the Technolas 217z ... for personalized vision correction, allows surgeons in ... to -7.00 Diopters and astigmatism up to ... combines both a 2mm and 1mm truncated ...
Medicine Products: